Mariner
LYEL icon

Mariner’s Lyell Immunopharma LYEL Stock Holding History

Mariner’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-704
Closed -$19.4K – 3469
2024
Q3 		$19.4K Sell
704
-4,261
-86% -$125K ﹤0.01% 3253
2024
Q2 		$144K Sell
4,965
-312
-6% -$14.9K ﹤0.01% 2876
2024
Q1 		$235K Sell
5,277
-468
-8% -$20K ﹤0.01% 2634
2023
Q4 		$223K Buy
5,745
+1,781
+45% +$64.1K ﹤0.01% 2604
2023
Q3 		$117K Buy
3,964
+1,816
+85% +$86.2K ﹤0.01% 2651
2023
Q2 		$137K Buy
2,148
+376
+21% +$20.8K ﹤0.01% 2573
2023
Q1 		$84K Buy
1,772
+1,263
+248% +$67.5K ﹤0.01% 2601
2022
Q4 		$35K Buy
+509
New +$50.6K ﹤0.01% 2643

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Mariner's LYEL Position: Q4 2024 in Review

Mariner sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 704 shares — an estimated $19.4K sold.

Mariner first reported a position in LYEL in Q4 2022 and held it in 8 quarters. The position peaked at $235K in Q1 2024. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Mariner reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Mariner sold 704 Lyell Immunopharma shares in Q4 2024, an estimated $19.4K.
  • Mariner first reported a position in Lyell Immunopharma in Q4 2022 and held it in 8 quarters.
  • Mariner's Lyell Immunopharma position peaked at $235K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Mariner's 13F filing for Q4 2024, filed 13 Feb 2025.